Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes

Clinical Cancer Research

Volumn 2, Issue 5, 1996, Pages 877-882

  Ciernik, I Frank ^a,c   Berzofsky, Jay A ^b   Carbone, David P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; EPITOPES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MUTATION, MISSENSE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030000287     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Yanuck, M., Carbone, D. P., Pendleton, C. D., Tsukui, T., Winter, S. F., Minna, J. D., and Berzofsky, J. A. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T cells. Cancer Res., 53: 3257-3261, 1993.
2. Ciernik, I. F., Berzofsky, J. A., and Carbone, D. P. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Hybridoma, 14: 139-142, 1995.
3. Takahashi, T., Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Anyoshi, Y., and Ueda, R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene, 6: 1775-1778, 1991.
4. Takahashi, T., Carbone, D., Takahashi, T., Nau, M. M., Hida, T., Linnoila, I., Ueda, R., and Minna, J. D. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res., 52: 2340-2343, 1992.
5. Cochet, M., Kast, W. M., Kummer, A-M., Transy, C., Melief, C. J. M., and Kourilsky, P. Alternative splicing in the mouse H-2Kd gene is not necessary for the classical Kd antigen function. Immunogenetics, 24: 267-274, 1986.
6. Takahashi, H., Houghten, R., Putney, S., Margulies, D., Moss, B., Germain, R., and Berzofsky, J. Structural requirements for class-I MHC molecule-mediated antigen presentation and cytotoxic T-cell recognition of an immunodominant determinant of the HIV envelope protein. J. Exp. Med., 170: 2023-2035, 1989.
7. Crumpacker, D. B., Alexander, I., Cresswell, P., and Engelhard, V. H. Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing. J. Immunol., 148: 3004-3011, 1992.
8. Anderson, K., Cresswell, P , Gammon, M., Hermes, J., Williamson, A., and Zweerink, H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J. Exp. Med., 174: 489-492, 1991.
9. Rivoltini, L., Barracchini, K. C , Viggiano, V., Kawakami, Y., Smith, A., Mixon, A., Restifo, N. P., Topalian, S. L., Simonis, T. B., Rosenberg, S. A., and Marincola, F. M. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res., 55: 3149-3157, 1995.
10. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E , Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
11. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
12. Bakker, A. B. H., Schreurs, M. W. J., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179: 1005-1009, 1994.
13. Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., Coulie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.
14. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B., Brasseur, F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179: 921-930, 1994.
15. Uenaka, A., Ono, T., Akisawa, T., Wada, H., Yasuda, T., and Nakayama, E. Identification of a unique antigen peptide pRL1 on BALB/c RL(male)1 leukemia recognized cytotoxic T lymphocytes and its relation to the akt oncogene. J. Exp. Med., 180: 1599-1607, 1994.
16. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
17. Peace, D. J., Chen, W., Helson, H., and Cheever, M. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J. Immunol., 146: 2059-2065, 1991.
18. Fenton, R. G., Taub, D. D., Kwak, L. W., Smith, M. R., and Longo, D. L. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J. Natl. Cancer Inst., 85: 1294-1302, 1993
19. Peace, D. J., Smith, J. W., Chen, W., You, S-G., Cosand, W. L., Blake, J., and Cheever, M. A. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J. Exp. Med., 179: 179-185, 1994.
20. Noguchi, Y., Chen, Y-T., and Old, L. J. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Natl. Acad. Sci. USA, 91: 3171-3175, 1994.
21. Qin, H., Chen, W., Takahashi, M., Disis, M. L., Byrd, D. R., McCahill, L., Bertram, K. A., Fenton, R. G., Peace, D. J., and Cheever, M. A. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res., 55: 2984-2987, 1995.
22. Gabrilovich, D I., Nadaf, S., Cunningham, T., Rogers, P., Kavanagh, D., Ciernik, I. F., Gazdar, A. F., Kelley, M. I., Smith, M. C., Berzofsky, J. A., and Carbone, D. P. Cytotoxic T-lymphocytes (CTL) specific for mutant p53-peptides in peripheral blood of patients with cancer: support for specific immune intervention. In: Proceedings of the 9th International Congress of Immunology, p. 668. San Francisco: American Association of Immunologists, 1995.
23. VanElsas, A., Nijman, H. W., VanDerMinne, C. E., Mourer, J. S., Kast, W. M., Melief, C. J. M., and Schrier, P. I. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int. J. Cancer, 61: 389-396, 1995.
24. Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mule, J. J., Rosenberg, S. A., and Bennink, J. R. Identification of human cancers deficient in antigen processing. J. Exp. Med., 177: 265-272, 1993.
25. Wiedenfeld, E. A., Fernandez-Vina, M., Berzofsky, J. A., and Carbone, D. P. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res., 54: 1175-1177, 1994.